Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

Abstract

Here, we show that HDAC inhibitors are a potential therapeutic option for B-ALL, and that a more specific inhibitor of HDAC1 and HDAC2 could be therapeutically useful for patients with B-ALL.